CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences, a privately held biopharmaceutical company focused on developing novel drugs using its expertise in Transient Receptor Potential (TRP) ion channels, announced today the expansion of its executive management team with the appointments of David Kimball, Ph.D. as Chief Scientific Officer and Christine Bellon, Ph.D. as Vice President of IP and Legal Affairs. Dr. Kimball most recently served as Senior Vice President, Discovery, at Pharmacopeia. Dr. Bellon joins Hydra from Infinity Pharmaceuticals, where she served as Assistant General Counsel, Intellectual Property.
